You are here:  > Browse Articles


Small molecule inhibitors of West Nile virus

Samia A Elseginy, Alberto Massarotti, Galal AM Nawwar, Kamilia M Amin, Andrea Brancale

Corresponding author name: Andrea Brancale
Corresponding author e-mail:

Citation: Antiviral Chemistry & Chemotherapy 2014; 23:179-187
doi: 10.3851/IMP2581

Date accepted: 09 April 2013
Date published online: 02 May 2013


West Nile virus (WNV) is a human pathogen which is rapidly expanding worldwide. It is a member of the Flavivirus genus and it is transmitted by mosquitos between its avian hosts and occasionally in mammalian hosts. In humans the infection is often asymptomatic, however, the most severe cases result in encephalitis or meningitis. Approximately 10% of cases of neuroinvasive disease are fatal. To date there is no effective human vaccine or effective antiviral therapy available to treat WNV infections. For this reason, research in this field is rapidly growing. In this article we will review the latest efforts in the design and development of novel WNV inhibitors from a medicinal chemistry point of view, highlighting challenges and opportunities for the researchers working in this field.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.